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3Nanoscale Test Strips for 
Multiplexed Blood Analysis   
Enables real-time, comprehensive health monitoring
A critical component of the DNA Medicine Institute’s Reusable Handheld 
Electrolyte and Lab Technology for Humans (rHEALTH) sensor are nanoscale 
test strips, or nanostrips, that enable multiplexed blood analysis. Nanostrips are 
conceptually similar to the standard urinalysis test strip, but the strips are shrunk 
down a billionfold to the microscale. Each nanostrip can have several sensor 
pads that ﬂuoresce in response to diﬀerent targets in a sample. The strips carry 
identiﬁcation tags that permit diﬀerentiation of a speciﬁc panel from hundreds 
of other nanostrip panels during a single measurement session.
In Phase I of the project, the company fabricated, tested, and demonstrated 
functional parathyroid hormone and vitamin D nanostrips for bone metabo-
lism, and thrombin aptamer and immunoglobulin G antibody nanostrips. In 
Phase II, numerous nanostrips were developed to address key space ﬂight–based 
medical needs: assessment of bone metabolism, immune response, cardiac 
status, liver metabolism, and lipid proﬁles. This unique approach holds genuine 
promise for space-based portable biodiagnostics and for point-of-care (POC) 
health monitoring and diagnostics here on Earth.
Applications
DNA Medicine Institute i llustration
NASA 
 ? Routine assessment of bone 
biomarkers
 ? Rapid assessment of altered 
immune response biomarkers
 ? Detection of infection,  
immunocompromised states,  
and hematological malignancies
 ? Measurement of cardiac 
biomarkers
 ? Liver function assessment
 ? Lipid measurements
Commercial
 ? Detection of acute myocardial 
damage
 ? POC monitoring of bisphospho-
nate therapy for patients with 
osteoporosis
 ? Diagnoses of acute cholecystitis
 ? Daily assessment of immune 
functions for patients with 
autoimmune disorders
 ? Study of bone remodeling for 
patients with Paget’s disease
 ? Evaluation of eﬀects of drugs and 
diet on liver function
Phase II Objectives
 ? Implement rapid nanostrip assay 
capability
 ? Develop mix-and-run assays
 ? Establish in-house aptamer 
production
 ? Develop lyophilized nanostrip 
technology with lyoprotectant:
?? Perform accelerated stability 
tests on lyophilized reagents
?? Perform extended testing on 
antibody and aptamer nanostrips 
 ? Develop bone antibody, bone 
aptamer, immune antibody, and 
immune aptamer nanostrip panel
 ? Develop cardiac, liver, and lipid 
assay nanostrip panels 
???????
 ? Enables massive multiplexing that 
has the potential to allow hundreds 
of measurements from a single 
session
 ? Facilitates home-based tests and 
measurements
 ? Contributes significantly to the 
evolving needs of space medicine, 
biomedical research, and POC 
diagnostics
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